Search PubMed⌕ Search

PubMed · 6503958

[Current problems in adrenal surgery].

Abstract

Retrospective study on diagnosis and management during the perioperative period of patients with adrenal tumors who underwent adrenalectomy in the Second Department of Surgery Kyoto University, from 1960 to 1983, was carried out. Most of the patients presented with functioning tumors; primary aldosteronism (43 cases), Cushing's syndrome (53 cases), pheochromocytoma (39 cases), and DOC-producing tumor (1 case), whereas, only 3 cases were non-functioning adenoma and cyst. Although recent development of CT has permitted easy and non-invasive diagnosis of adrenal tumors, aldosterone-producing tumors may be overlooked due to their small sizes, because their CT value is identical to that of fatty tissue. Moreover, blood sampling from vena cava at various levels is also necessary in patients with extra-adrenal pheochromocytomas. The preoperative control of blood pressure by alpha- and beta-adrenergic blocking agents was a prerequisite, and the clinical course was uneventful following intraoperative additive use of sodium nitroprusside in patients with pheochromocytoma. Autotransplantation of the adrenal cortex into the rectus muscle was performed in three patients with bilateral pheochromocytoma and two of them could return to work. Non-functioning adrenal tumors have been found increasingly by routine CT study without previous suspicion and the surgical indication of these tumors must be discussed in more detail in the future.

Explore related subjects

Keep this discovery

Explore connections, maps & timelines

BibTeXRIS

H Tanimura, N Kobayashi. 1984. [Current problems in adrenal surgery].. https://pubmed.ncbi.nlm.nih.gov/6503958/

Cite the original work for its findings. Save a collection to share your selection of sources.

KEEP EXPLORING

Related citations

Treatment of neuroblastoma-related opsoclonus-myoclonus-ataxia syndrome with high-dose dexamethasone pulses.

Opsoclonus-myoclonus-ataxia-syndrome (OMS) represents a rare neuroblastoma-associated paraneoplastic syndrome that commonly results in neurologic deficits despite tumor resection and immunosuppressive therapy. We describe the response of five such children to high-dose dexamethasone pulses including two patients in whom previous glucocorticoids, rituximab, and cytostatic drugs were not successful. All patients had MYCN non-amplified tumors that were detected 1 to 7 months after the onset of the OMS or ataxia. This treatment resulted in a good partial response in three and in complete remission in two patients. Our results show that dexamethasone pulses are likely to be useful for both, first-line- and salvage-therapy for OMS-patients.

Adrenal Gland Neoplasms↗

Malignant paragangliomas associated with mutations in the succinate dehydrogenase D gene.

INTRODUCTION: Malignant paragangliomas have been well described in carriers of mutations of the succinate dehydrogenase B (SDHB) gene, but have rarely been associated with mutations in the succinate dehydrogenase D (SDHD) gene. AIM: The aim of the study was to report the different clinical expression patterns of malignant paragangliomas in five patients with SDHD (D92Y) mutations observed in approximately 200 SDHD (D92Y) mutation carriers followed in our institution. RESULTS: Metastasis and/or local tumor invasion was documented 0 (n=2), 1, 18, and 30 yr after the initial diagnosis of paraganglioma. Malignancy was proven by paraganglioma bone metastases (n=2), intrathoracic paraganglioma with lymph node metastases, locally invasive head-and-neck paraganglioma with destruction of the petrosal bone, and locally invasive paraganglioma of the bladder with lymph node metastases. Four of the five patients developed catecholamine excess during follow-up due to intraadrenal paraganglioma (pheochromocytoma) (n=1), extra adrenal paraganglioma (n=2), and presumed subclinical disease (n=1). CONCLUSION: SDHD mutations (D92Y) are associated with malignant paragangliomas and catecholamine excess with remarkable interindividual variations despite the same mutation. We estimate that the prevalence of malignancy in carriers of D92Y mutations is at least 2.5%.

Adrenal Gland Neoplasms↗